# OnCo record paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013" ;
  schema:name "Nimotuzumab or placebo with radiotherapy for high-grade glioma: a Cuban randomised double-blind trial"@en ;
  schema:description "In 70 Cuban patients with high-grade glioma, adding the anti-EGFR antibody nimotuzumab to radiotherapy gave a median survival of 17.8 months against 12.6 months with placebo. The abstract's background says the antibody does not cause the skin toxicity of other anti-EGFR antibodies; that is not reported as a result of this trial."@en ;
  schema:url <https://onco.cc/key-papers/paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  schema:citation <https://doi.org/10.1186/1471-2407-13-299>, <https://pubmed.ncbi.nlm.nih.gov/23782513/>, <https://www.cecmed.cu/registro/rcp/biologicos/cimaherr-nimotuzumab> ;
  schema:sameAs <https://doi.org/10.1186/1471-2407-13-299> ;
  schema:datePublished "2013"^^xsd:gYear ;
  schema:author "Solomón MT, Selva JC, Figueredo J, et al." ;
  onco:related <https://onco.cc/institutions/cencec-cuba/> ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/nimotuzumab/> ;
  onco:companies <https://onco.cc/companies/cimab/> .
